Cancer, Advanced Undifferentiated Pleomorphic Sarcoma/Dedifferentiated Liposarcoma
IOVAIovance BiotherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Amtagvi/Lifileucel (LN-144) (TIL Therapy) in Cancer, Advanced Undifferentiated Pleomorphic Sarcoma/Dedifferentiated Liposarcoma. The expected timing is based on the latest available company guidance and may change.
02/24/26:- Pilot UPS/DDLPS trial shows 50% ORR. Single-arm registrational trial starts Q2 2026. Present data at 2026 conference. 05/07/26:- IOV-SAR-201 registrational trial underway; site activation and enrollment expected Q3 2026; expedited approval discussions ongoing. 08/06/26:- SARATOGA FTD granted; 50% ORR; ESMO data expected October 23-27, 2026.
Verification
Confirm timing and program details against the company announcement or filing.